Loading clinical trials...
Loading clinical trials...
Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA Trial)
Conditions
Interventions
Durvalumab
Oleclumab
Locations
1
Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
November 29, 2023
Primary Completion Date
October 30, 2026
Completion Date
October 30, 2026
Last Updated
January 8, 2024
NCT04657068
NCT06445062
NCT04900818
NCT07432633
NCT04851119
NCT06005493
Lead Sponsor
University Health Network, Toronto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions